China's 2026 dual-list overhaul puts 51 Class 1 drugs into NRDL, cuts prices on high-cost therapies
NHSA Notice No. 29 of 2026 adds 107 drugs (51 Class 1) to basic NRDL and expands the commercial list to 28 from Jan 1, 2027, cutting 60%+ of candidates at expert review and delisting four non-renewed drugs.